Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cardinal Health has recently announced its financial results for the second quarter of fiscal year 2024.</li><li>CEO Jason Hollar and CFO Aaron Alt expressed satisfaction with the progress the company has made, demonstrating strong profit growth in both segments and expected growth for 7% to 9% in segment profit for fiscal 2024.</li><li>Cardinal Health's acquisition of Specialty Networks is seen as a key step in enhancing the company's specialty growth strategy.</li></ul>

Cardinal Health has recently announced its financial results for the second quarter of fiscal year 2024.CEO Jason Hollar and CFO Aaron Alt expressed satisfaction with the progress the company has made, demonstrating strong profit growth in both segments and expected growth for 7% to 9% in segment profit for fiscal 2024.Cardinal Health's acquisition of Specialty Networks is seen as a key step in enhancing the company's specialty growth strategy.

Cardinal Health: Expanding Acquisitions Portfolio With Specialty Networks & Other Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

NASDAQ Composite Index / Technical Analysis

<ul>
<li>Following last week's pullback, a consistent theme we are seeing is that many broad market indexes and Sector ETFs are holding above (and bouncing at) major base supports.</li>
<li>As long as these base supports continue to hold, it tells us this is likely just a normal pullback within the overall bullish trend.</li>
<li>Important supports that we need to see hold in order to remain bullish include 4600 on the S&amp;P 500 and 14,400 on the Nasdaq Composite.</li>
</ul>


Following last week's pullback, a consistent theme we are seeing is that many broad market indexes and Sector ETFs are holding above (and bouncing at) major base supports.
As long as these base supports continue to hold, it tells us this is likely just a normal pullback within the overall bullish trend.
Important supports that we need to see hold in order to remain bullish include 4600 on the S&amp;P 500 and 14,400 on the Nasdaq Composite.


Major Base Supports Holding; DXY Testing the 2-Month Downtrend; 4600 on SPX Remains Key Support

<ul><li>Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant milestones.</li><li>Consolidated enterprise results showcased a 10% increase in total revenue to $54.8 billion, primarily fueled by the Pharma segment.</li><li>Despite flat revenue of $3.8 billion in the Medical segment, the company exceeded expectations in Q1.</li></ul>

Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant milestones.Consolidated enterprise results showcased a 10% increase in total revenue to $54.8 billion, primarily fueled by the Pharma segment.Despite flat revenue of $3.8 billion in the Medical segment, the company exceeded expectations in Q1.

Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! - Major Drivers

<ul>
<li>Expectations since late-September remain unchanged; if $SPX is above 4165-4200/200-day MA, we're bullish, as most signs point to this being a normal pullback within the ongoing bullish trend in SPX.</li>
<li>As discussed last week (10/11/23), we have growing confidence that lows are likely in on the SPX, which made a low at 4216 (with 4200 hit exactly overnight 10/4/23).</li>
<li>We also discussed Russell 2000 breadth bottoming last week, and this has continued with bullish breadth divergences on Russell 2000 % of stocks above their 50- and 200-day MAs</li>
</ul>


Expectations since late-September remain unchanged; if $SPX is above 4165-4200/200-day MA, we're bullish, as most signs point to this being a normal pullback within the ongoing bullish trend in SPX.
As discussed last week (10/11/23), we have growing confidence that lows are likely in on the SPX, which made a low at 4216 (with 4200 hit exactly overnight 10/4/23).
We also discussed Russell 2000 breadth bottoming last week, and this has continued with bullish breadth divergences on Russell 2000 % of stocks above their 50- and 200-day MAs


Russell 2000 With Bullish Breadth Divergences; Buys in Insurance and Health Care Distributors

<ul><li>Cardinal Health Inc. delivered a positive result and managed an all-around beat last quarter.</li><li>The Pharma segment demonstrated remarkable profit growth of 13%, and the company generated significant adjusted free cash flow amounting to $2.8 billion.</li><li>Cardinal Health pursued determined actions to advance its strategic imperatives, streamlining its operations, optimizing its organizational structure, and instituting fundamental leadership changes.</li></ul>

Cardinal Health Inc. delivered a positive result and managed an all-around beat last quarter.The Pharma segment demonstrated remarkable profit growth of 13%, and the company generated significant adjusted free cash flow amounting to $2.8 billion.Cardinal Health pursued determined actions to advance its strategic imperatives, streamlining its operations, optimizing its organizational structure, and instituting fundamental leadership changes.

Cardinal Health Inc.: How Their Pioneering NTrainer System 2.0 is Changing Neonatal Care Forever! - Major Drivers

United States

Cardinal Health, Inc. provides complementary products and services to healthcare providers and manufacturers.  The Company's services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cardinal Health (CAH US)

Cardinal Health: Expanding Acquisitions Portfolio With Specialty Networks & Other Major Drivers

Cardinal Health has recently announced its financial results for the second quarter of fiscal year 2024. CEO Jason Hollar and CFO Aaron Alt...

Baptista Research

Major Base Supports Holding; DXY Testing the 2-Month Downtrend; 4600 on SPX Remains Key Support

A consistent theme we are seeing is that many broad market indexes and Sector ETFs are holding above (and bouncing at) major base supports...

Vermilion Research

Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! - Major Drivers

Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant...

Baptista Research

Russell 2000 With Bullish Breadth Divergences; Buys in Insurance and Health Care Distributors

Our view since late Sept remains unchanged: if $SPX is above 4165-4200 and the 200-day MA, we are bullish, as most signs point to this being a...

Vermilion Research

Cardinal Health Inc.: How Their Pioneering NTrainer System 2.0 is Changing Neonatal Care Forever! - Major Drivers

Cardinal Health Inc. delivered a positive result and managed an all-around beat last quarter. The Pharma segment demonstrated remarkable profit...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)